Imperfect gold standards for biomarker evaluation
| Autor: | Sushrut S. Waikar, Sarah C. Emerson, Joseph V. Bonventre, Rebecca A. Betensky |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty Pathology Sensitivity and Specificity Article chemistry.chemical_compound Renal Dialysis Internal medicine Prevalence Humans Medicine False Positive Reactions False Negative Reactions Pharmacology Creatinine business.industry Extramural Acute kidney injury Diagnostic test General Medicine Gold standard (test) Acute Kidney Injury medicine.disease ROC Curve chemistry Biomarker (medicine) Creatinine blood business Biomarkers |
| Zdroj: | Clinical Trials. 10:696-700 |
| ISSN: | 1740-7753 1740-7745 |
| Popis: | Background Serum creatinine has been used as the diagnostic test for acute kidney injury (AKI) for decades despite having imperfect sensitivity and specificity. Novel tubular injury biomarkers may revolutionize the diagnosis of AKI; however, even if a novel tubular injury biomarker is 100% sensitive and 100% specific, it may appear inaccurate when using serum creatinine as the gold standard. Conclusions In general, the apparent diagnostic performance of a biomarker depends not only on its ability to detect injury but also on disease prevalence and the sensitivity and specificity of the imperfect gold standard. Apparent errors in diagnosis using a new biomarker may be a reflection of errors in the imperfect gold standard itself rather than poor performance of the biomarker. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|